



IFW


DOCKET NO.: P0741.70006US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Maddon et al.  
Serial No.: 10/695,667  
Confirmation No.: 4456  
Filed: October 27, 2003  
For: PSMA FORMULATIONS AND USES THEREOF  
Examiner: Stephen L. Rawlings  
Art Unit: 1643

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 13<sup>th</sup> day of December, 2005.

  
Emily E. Lukauskas

**MAIL STOP AMENDMENT**

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:


- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

  
Janice A. Vatland, Ph.D., Reg. No.: 52,318  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: P0741.70006US00  
Date: December 13, 2005  
xNDDx



DOCKET NO.: P0741.70006US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Maddon et al.  
Serial No.: 10/695,667  
Confirmation No.: 4456  
Filed: October 27, 2003  
For: PSMA FORMULATIONS AND USES THEREOF  
Examiner: Stephen L. Rawlings  
Art Unit: 1643

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 13<sup>th</sup> day of December, 2005.

  
Emily E. Lukauskas

---

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. §1.97**

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the enclosed search report or other type of communication from a corresponding or other International or Foreign National Application.

<u>Serial No.</u>	<u>Mailing Date</u>	<u>Type(s) of Communication</u>	<u>Docket No.</u>
PCT/US2004/036120	May 11, 2005	Invitation to Pay Additional Fees	P0741.70007WO00
PCT/US2004/036120	August 16, 2005	International Search Report and Written Opinion	P0741.70007WO00

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.


An early and favorable action is hereby requested.

Respectfully submitted,

By:

  
Janice A. Vatland, Ph.D., Reg. No. 52,318  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: P0741.70006US00  
Date: December 13, 2005  
xNDDx



<p>FORM PTO-1449/A and B (modified PTO/SB/08)</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p>	DEC 15 2005	APPLICATION NO.:	10/695,667	ATTY. DOCKET NO.:	P0741.70006US00
	RECEIVED	FILING DATE:	October 27, 2003	CONFIRMATION NO.:	4456
	RECEIVED	APPLICANT:	Maddon et al.		
	RECEIVED	GROUP ART UNIT:	1643	EXAMINER:	Stephen L. Rawlings
Sheet	1	of	2		

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	BARINKA et al., Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. <i>J Neurochem.</i> 2002 Feb;80(3):477-87.	
	C2	MA et al., PSMA-targeted toxin- and radio-labelled antibody therapies for prostate cancer. <i>J Urology.</i> 2003 Apr;169(4):211. Poster 817.	
	C3	MA et al., Fully human anti-PSMA antibodies for prostate cancer therapy. <i>Proceedings of the American Association for Cancer Research Annual Meeting.</i> 2003 July;44:1295. Poster 6471.	
	C4	SCHÜLKE et al., The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. <i>Proc Natl Acad Sci U S A.</i> 2003 Oct 28;100(22):12590-5.	
	C5	SCHÜLKE et al., Human Prostate Specific Membrane Antigen (PSMA) is expressed as a non-covalent dimer and provides an attractive target for cancer immunotherapy. <i>Eur J Cancer.</i> 2002 Nov;38:S153. Poster 510.	

EXAMINER: DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/695,667	ATTY. DOCKET NO.: P0741.70006US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 27, 2003	CONFIRMATION NO.: 4456
				APPLICANT: Maddon et al.	
Sheet	2	of	2	GROUP ART UNIT: 1643	EXAMINER: Stephen L. Rawlings

	C6	SOKOLOFF et al., A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. <i>Prostate</i> . 2000 May 1;43(2):150-7.	
	C7	SPENO et al., Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. <i>Mol Pharmacol</i> . 1999 Jan;55(1):179-85.	
	C8	TROYER et al., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. <i>Int J Cancer</i> . 1995 Sep 4;62(5):552-8.	
	C9	XIAO et al., Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. <i>Protein Expr Purif</i> . 2000 Jun;19(1):12-21.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.